phthalocyanine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Z; Gong, Z; Jiang, X; Li, R; Liu, Y; Sun, D; Zeng, W; Zheng, G; Zhou, Y | 1 |
| Chen, J; Huang, K; Xue, J; Yan, M; Zhang, H | 1 |
| Amoury, M; Barth, S; Bauerschlag, D; Berges, N; Bleilevens, A; Bräutigam, K; Di Fiore, S; Fischer, R; Hussain, AF; Maass, N; Meinhold-Heerlein, I; Mintert, I; Stickeler, E; von Felbert, V; Zeppernick, F | 1 |
3 other study(ies) available for phthalocyanine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer.
Topics: Animals; Cell Line, Tumor; Humans; Isoindoles; Mice; Oligopeptides; Photochemotherapy; Triple Negative Breast Neoplasms | 2022 |
A phthalocyanine-based photosensitizer for effectively combating triple negative breast cancer with enhanced photodynamic anticancer activity and immune response.
Topics: Cell Line, Tumor; Humans; Immunity; Isoindoles; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2022 |
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
Topics: Cell Line, Tumor; Cell Survival; Chondroitin Sulfate Proteoglycans; Epithelial Cell Adhesion Molecule; ErbB Receptors; Female; Guanine; Humans; Immunoconjugates; Indoles; Isoindoles; Light; MCF-7 Cells; Membrane Proteins; Microscopy, Confocal; Organosilicon Compounds; Photochemotherapy; Photosensitizing Agents; Recombinant Fusion Proteins; Single-Chain Antibodies; Triple Negative Breast Neoplasms | 2016 |